Literature DB >> 2524877

Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes.

S L Hoffman1, D Isenbarger, G W Long, M Sedegah, A Szarfman, L Waters, M R Hollingdale, P H van der Meide, D S Finbloom, W R Ballou.   

Abstract

The target of the CD8+ T cell-dependent immunity that protects mice immunized with irradiation-attenuated malaria sporozoites has not been established. Immune BALB/c mice were shown to develop malaria-specific, CD8+ T cell-dependent inflammatory infiltrates in their livers after challenge with Plasmodium berghei sporozoites. Spleen cells from immune BALB/c and C57BL/6 mice eliminated hepatocytes infected with the liver stage of P. berghei in vitro. The activity against infected hepatocytes is not inhibited by antibodies to interferon-gamma and is not present in culture supernatants. It is genetically restricted, an indication that malaria antigens on the hepatocyte surface are recognized by immune T effector cells. Subunit vaccine development will require identification of the antigens recognized by these T cells and a method of immunization that induces such immunity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524877     DOI: 10.1126/science.2524877

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  50 in total

1.  Dendritic cells can initiate protective immune responses against malaria.

Authors:  O Bruña-Romero; A Rodriguez
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

3.  Survival and antigenic profile of irradiated malarial sporozoites in infected liver cells.

Authors:  A Suhrbier; L A Winger; E Castellano; R E Sinden
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

4.  Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids.

Authors:  R Wang; D L Doolan; Y Charoenvit; R C Hedstrom; M J Gardner; P Hobart; J Tine; M Sedegah; V Fallarme; J B Sacci; M Kaur; D M Klinman; S L Hoffman; W R Weiss
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 5.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

Review 6.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

7.  Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.

Authors:  B Wizel; R A Houghten; K C Parker; J E Coligan; P Church; D M Gordon; W R Ballou; S L Hoffman
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

8.  Tomatine adjuvantation of protective immunity to a major pre-erythrocytic vaccine candidate of malaria is mediated via CD8+ T cell release of IFN-gamma.

Authors:  Karen G Heal; Andrew W Taylor-Robinson
Journal:  J Biomed Biotechnol       Date:  2010-03-11

9.  Transcriptional analysis of the pre-erythrocytic stages of the rodent malaria parasite, Plasmodium yoelii.

Authors:  Calvin T Williams; Abdu F Azad
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

10.  In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages.

Authors:  Ian A Cockburn; Rogerio Amino; Reka K Kelemen; Scot C Kuo; Sze-Wah Tse; Andrea Radtke; Laura Mac-Daniel; Vitaly V Ganusov; Fidel Zavala; Robert Ménard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.